Ipsen Sa · EURONEXT:IPN
Ipsen Sa — Merger or Acquisition (January 2017)
16 slides from Ipsen Sa's merger presentation, Jan 9, 2017
Slide 1: Ipsen Acquisition of Oncology Assets from Merrimack Pharmaceuticals
Ipsen Acquisition of Oncology Assets from Merrimack Pharmaceuticals Accelerating Ipsen’s Oncology Capabilities and Leadership Position, Fueling Near- and Long-Term Growth January 9, 2017 IPSEN pour nom de la société - 07/04/2011 / page 1
Slide 2: Disclaimer / Safe Harbor
Disclaimer This presentation includes only summary information and does not purport to be comprehensive. Forward-looking statements, targets and estimates contained herein are for illustrative purposes only and are based on management’s current views and assumptions. Such statements involve known an
Slide 3: Acquisition of oncology assets from Merrimack Pharmaceuticals
Acquisition of oncology assets from Merrimack Pharmaceuticals - Key product ONIVYDE® Approved for the treatment of patients with metastatic pancreatic cancer following gemcitabine-based therapy, in combination with fluorouracil and leucovorin - Generic doxorubicin HCl liposome injection Rights for c
Slide 4: Unique transaction with compelling rationale
Unique transaction with compelling rationale Strategic Clinically differentiated FDA approved product for patients with high unmet medical needs Unique opportunity to secure a marketed wholly-owned asset with current U.S. revenues, based on solid clinical data and potential approvals in addition
Slide 5: Accelerating transformation of Ipsen
Accelerating transformation of Ipsen Strengthening Growing U.S. Increasing growth Oncology focus presence and profitability • Emerging as • U.S. establishing • Substantial synergies to recognized market meaningful presence further leverage leader in several in oncology market profitability with limi
Slide 6: New product in tumor with high unmet medical need
New product in tumor with high unmet medical need with overall survival data and established safety profile Differentiated product for metastatic pancreatic cancer First and only FDA-approved therapy in post-gemcitabine pancreatic cancer Novel encapsulation of irinotecan Superior PK profile
Slide 7: Highly differentiated and novel formulation of irinotecan
Highly differentiated and novel formulation of irinotecan The liposome is designed to keep irinotecan in circulation and in the tumors IRI Long Half-Life ONIVYDE Longer half life keeps drug circulating in the IRI IRI IRI system longer Increase and prolong intra-tumor levels IRI of drug Incre
Slide 8: Significant commercial opportunity in metastatic pancreatic cancer in the U.S.
Significant commercial opportunity in metastatic pancreatic cancer in the U.S. ~50,000 Pancreatic Cancer Patients (1) ONIVYDE approved for the treatment of patients with metastatic adenocarcinoma Resectable? Yes -- Surgery of the pancreas after disease progression following gemcitabine-based therapy
Slide 9: Few improvements to the pancreatic cancer treatment paradigm in 20 years
There have been few improvements to the treatment paradigm in the last 20 years… 1996 1996 2005 2005 2010 2010 2013 2013 2015 2015 nab-Paclitaxel Gemcitabine + Nanoliposomal Gemcitabine FOLFIRINOX (Abraxane) + Erlotinib irinotecan (FFX) Gemcitabine (Nab- (ONIVYDE) Improved survival P/G) Improved sur
Slide 10: ONIVYDE development program provides upside potential
ONIVYDE development program provides upside potential INDICATION PHASE I PHASE II PHASE III Previously Untreated Metastatic Pancreatic Cancer Relapsed small cell lung cancer Breast Cancer (Metastatic(1)) 3 19 ONIVYDE Franchise Ongoing programs partnered Ongoing investigator-initiated Exploring furth
Slide 11: U.S. oncology commercial organizational expertise to accelerate growth
U.S. oncology commercial organizational expertise to accelerate growth trajectory and maximize product potential Current team with extensive experience in oncology treating pancreatic cancer Track record of successfully launching to key stakeholders in the pancreatic cancer market, making ONIVYDE a
Slide 12: Financial terms of transaction
Financial terms of transaction Cash consideration of $575 million payable at closing Additional contingent payments up to $450 million upon approval of additional indications in the U.S. Transaction to be fully financed with existing cash and long-term lines of credit (€600 million) Licensing agreem
Slide 13: Financial impact for Ipsen
Financial impact for Ipsen ONIVYDE net sales run rate of $60 million(1) (12 months after launch) Significant transaction synergies with existing U.S. commercial organization Shire partnership meaningful contribution to share future development costs Transaction expected to be dilutive in 201
Slide 14: Next steps to closing
Next steps to closing Closing timeline • Subject to customary closing conditions, including governmental regulatory clearances • Subject to approval by Merrimack shareholders • Expected by end of Q1 2017 Integration • Transfer of manufacturing facility and supply chain • Transfer of over 100 employe
Slide 15: Ipsen establishing global leadership in specialty Oncology markets
Ipsen establishing global leadership in specialty Oncology markets Prostate Neuroendocrine Renal Cell Pancreatic Cancer Tumors (NET) Carcinoma Cancer Mature but Best-in-class Ongoing EU Differentiated growing SSA leadership launch in 2L product for product in EU position in NET RCC supported high un
Slide 16: Thank you
Thank you